DK1976532T3 - Hurtigvirkende inhibitor af mavesyresekretion - Google Patents

Hurtigvirkende inhibitor af mavesyresekretion Download PDF

Info

Publication number
DK1976532T3
DK1976532T3 DK07716990.2T DK07716990T DK1976532T3 DK 1976532 T3 DK1976532 T3 DK 1976532T3 DK 07716990 T DK07716990 T DK 07716990T DK 1976532 T3 DK1976532 T3 DK 1976532T3
Authority
DK
Denmark
Prior art keywords
zinc
gastric
composition
stomach
acid
Prior art date
Application number
DK07716990.2T
Other languages
English (en)
Inventor
John P Geibel
Philipp Kirchhoff
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Application granted granted Critical
Publication of DK1976532T3 publication Critical patent/DK1976532T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Claims (16)

1. Farmaceutisk sammensætning til administration til maven hos en patient omfattende en effektiv mængde af mindst et farmaceutisk acceptabelt zinksalt i kombination med en protonpumpeinhibitor, eventuelt i kombination med en farmaceutisk acceptabel bærer, et additiv eller en excipiens til anvendelse til hurtigt at øge pH-værdien i mavesafterne i maven hos en patient som har behov derfor til mindst 3,0 inden for et tidsrum som ikke er mere end en time efter administration.
2. Sammensætning til anvendelse ifølge krav 1 hvor mængden af zinksalt i sammensætningen er effektiv til at øge pH-værdien i mavesafterne i maven hos patienten til mindst 3,5 inden for et tidsrum som ikke er mere end 30 minutter efter administration.
3. Sammensætning til anvendelse ifølge krav 1 eller 2 hvor mængden af zinksalt er effektiv til at øge pH-værdien i mavesafterne i maven hos patienten til mindst 4,0.
4. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-3 hvor zinksaltet er valgt fra gruppen bestående af zinkacetat, zinkascorbat, zinkbutryat, zinkcarbonat, zinkcitrat, zinkchlorid, zinkiodid, zinksulfat, zinkgluconat, zinkglycerat, zinkglycolat, zinkformat, zinklactat, zinkpicolinat, zinksalicylat, zinktartrat, zinkundecylenat, et zinkaminosyrechelat og blandinger deraf.
5. Sammensætning til anvendelse ifølge krav 4 hvor zinksaltet er valgt fra gruppen bestående af zinkacetat, zinkascorbat, zinkcitrat, zinkchlorid, zinksulfat, zinkgluconat, zinkpicolinat, et zinkaminosyrechelat eller blandinger deraf.
6. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 3 hvor zinksaltet er valgt blandt mindst to zinksalte fra gruppen bestående af zinkacetat, zinkascorbate, zinkcitrat, zinkchlorid, zinkgluconat, zinkpicolinat og et zinkaminosyrechelat.
7. Sammensætning til anvendelse ifølge kravene 1-6 hvor zinksaltet eller mindst et af zinksaltene er et zinkaminosyrechelat.
8. Sammensætning til anvendelse ifølge krav 7 hvor zinkaminosyrechelatet er valgt fra gruppen bestående af mono- og bis-chelater fra L- eller D- aminosyrer.
9. Sammensætning til anvendelse ifølge kravene 7 eller 8 hvor aminosyrechelatet er et chelat af zink med en aminosyre valgt fra gruppen bestående af L-cystein, L-cystin, L-N-acetylcystein, L-histidin, D-histidin, L-taurin, L-glycinat, L-aspartat og L-methionin.
10. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-3 hvor zinksaltet er zinkchlorid og eventuelt, mindst et yderligere zinksalt valgt blandt gruppen bestående af zinkacetat, zinkascorbat, zinkcitrat, zinkgluconat, zinkpicolinat, zinksulfat og et zinkaminosyrechelat.
11. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-10 hvor protonpumpeinhibitoren er esomeprazol, lansoprazol, omeprazol, pantoprazol, rabeprazol eller blandinger deraf.
12. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-11 hvor protonpumpeinhibitoren er en blanding af esomeprazol, lansoprazol, omeprazol, pantoprazol eller rabeprazol.
13. Sammensætning ifølge et hvilket som helst af kravene 1-11 hvor protonpumpeinhibitoren er formuleret til en langsom frigivelsesform.
14. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-13 omfattende mindst to zinksalte, idet mindst et af zinksaltene er formuleret til en øjeblikkelig frigivelsesform og mindst et zinksalt er formuleret til en langsom frigivelsesform.
15. Sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvor sammensætningen er en væskesammensætning.
16. Sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvor sammensætningen er egnet til oral administration.
DK07716990.2T 2006-01-27 2007-01-25 Hurtigvirkende inhibitor af mavesyresekretion DK1976532T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US76259506P 2006-01-27 2006-01-27
US76483406P 2006-02-03 2006-02-03
US85089106P 2006-10-11 2006-10-11
PCT/US2007/001950 WO2007089511A2 (en) 2006-01-27 2007-01-25 Fast acting inhibitor of gastric acid secretion

Publications (1)

Publication Number Publication Date
DK1976532T3 true DK1976532T3 (da) 2016-02-01

Family

ID=38327882

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07716990.2T DK1976532T3 (da) 2006-01-27 2007-01-25 Hurtigvirkende inhibitor af mavesyresekretion

Country Status (15)

Country Link
US (1) US11510894B2 (da)
EP (2) EP2705845B1 (da)
JP (3) JP5469865B2 (da)
CN (2) CN101374526B (da)
CA (1) CA2635272C (da)
DK (1) DK1976532T3 (da)
ES (2) ES2609976T3 (da)
HK (1) HK1191861A1 (da)
HR (1) HRP20151437T1 (da)
HU (1) HUE029222T2 (da)
PL (1) PL1976532T3 (da)
PT (1) PT1976532E (da)
RS (1) RS54543B1 (da)
SI (1) SI1976532T1 (da)
WO (1) WO2007089511A2 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512761B2 (en) 2006-01-27 2013-08-20 Yale University Fast acting inhibitor of gastric acid secretion
US11510894B2 (en) 2006-01-27 2022-11-29 John P. Geibel Fast acting inhibitor of gastric acid secretion
WO2009114098A2 (en) * 2008-03-03 2009-09-17 Amgen Inc. Methods of treating hyperacidic disorders
JP2010184914A (ja) * 2009-02-13 2010-08-26 Bizen Chemical Co Ltd プロトンポンプ阻害活性を有する組成物
US20110038852A1 (en) * 2009-06-10 2011-02-17 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
JP2013509443A (ja) * 2009-11-01 2013-03-14 シンセティック バイオロジックス，インコーポレイテッド 胃保持性の経口用高用量亜鉛調製物
WO2011143503A2 (en) 2010-05-12 2011-11-17 Rempex Pharmaceuticals, Inc. Tetracycline compositions
US20140039004A1 (en) * 2012-07-31 2014-02-06 Ono Pharmaceutical Co., Ltd. Method of treating of gastroesophageal reflux disease
WO2015153552A1 (en) * 2014-03-31 2015-10-08 Yale University Fast acting inhibitor of gastric acid secretion with enhanced activity
CN105232506A (zh) * 2015-11-04 2016-01-13 温州医科大学 丁酸及其盐在制备治疗或预防胃溃疡药物中的应用
CN105769840B (zh) * 2016-04-01 2018-06-29 温州医科大学 乙酸及其盐的应用
RU2659955C1 (ru) * 2017-10-26 2018-07-04 Галина Ильхамовна Лукина Способ диагностики высоких гастроэзофагеальных рефлюксов
CA3123234A1 (en) * 2018-12-20 2020-06-25 Colgate-Palmolive Company Oral care composition comprising zinc and an amino acid for treating symptoms of a gastric disorder in the oral cavity
CN111388436A (zh) * 2020-04-20 2020-07-10 北京健讯医药科技有限公司 一种海藻酸钠咀嚼片及其制备方法
CN114908314B (zh) * 2022-05-16 2023-11-28 浙江飞剑工贸有限公司 一种能持久微量释放金属离子的抗菌涂层及其制备方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE393532B (sv) * 1974-05-02 1977-05-16 Draco Ab Sett att framstella en farmaceutisk zinkberedning for astadkommande av en smaklig, fordragbar, peroral zinklosning innehallande ett zinkkomplex
US4863741A (en) 1985-03-25 1989-09-05 Abbott Laboratories Tablet composition for drug combinations
US4940556A (en) 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
EP0265061B1 (en) 1986-09-18 1992-01-08 London School of Pharmacy Innovations Ltd Pharmaceutical formulation
JPH07116160B2 (ja) 1987-08-10 1995-12-13 浜理薬品工業株式会社 結晶性ｌ−カルノシン亜鉛錯体およびその製造法
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
AUPM456894A0 (en) * 1994-03-18 1994-04-14 Glyzinc Pharmaceuticals Limited Treatment for gastric disorders
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
HU225329B1 (en) * 1996-09-12 2006-09-28 Richter Gedeon Vegyeszet Use of zinc or cobalt hyaluronate associate for the manufacture of pharmaceutical compositions of antimicrobial activity
GB9621273D0 (en) * 1996-10-11 1996-11-27 Cortecs Ltd Therapeutic method
US20030068326A1 (en) * 1998-05-15 2003-04-10 Aphton Corporation Method for the treatment of gastroesophageal reflux disease
US7816403B2 (en) * 1998-09-08 2010-10-19 University Of Utah Research Foundation Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same
US6166071A (en) * 2000-03-13 2000-12-26 Albion International, Inc. Zinc amino acid chelates having ligands comprised of glycine and a sulfur-containing amino acids
US6576634B1 (en) * 2000-07-07 2003-06-10 N.V. Nutricia Pharmaceutical or dietetic preparation for improvement of fertility and sperm quality
MXPA03000848A (es) * 2000-07-28 2004-12-13 Immupharm Aps Metodos para el tratamiento de sintomas del resfriado comun, rinitis alergica e infecciones relacionadas con el tracto respiratorio.
US20020198165A1 (en) * 2000-08-01 2002-12-26 Bratzler Robert L. Nucleic acids for the prevention and treatment of gastric ulcers
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
EP1262172A1 (en) * 2001-05-25 2002-12-04 Italmed S.N.C. Di Galli G. & Pacini G. Liquid polymer composition for prevention and treatment of the oral cavity diseases
US7026298B2 (en) * 2001-06-04 2006-04-11 Abbott Laboratories Oral rehydration compositions
FI20011403A (fi) * 2001-06-29 2002-12-30 Carbion Oy Menetelmä ja koostumukset vatsan sairauksien hoitoon
US6930099B2 (en) * 2001-09-07 2005-08-16 Advanced Medical Instruments Composition for the treatment and prevention of endothelial dysfunction
US6596708B1 (en) * 2001-09-07 2003-07-22 Advanced Medical Instruments Composition for the treatment and prevention of endothelial dysfunction
US6632449B2 (en) * 2001-11-20 2003-10-14 The Procter & Gamble Co. Compositions and kits comprising a defined boron compound and methods of their preparation
EP1480517A4 (en) 2002-02-07 2007-08-22 Univ Columbia ZINC SALT COMPOSITIONS FOR PREVENTING MOLECULAR BREAST EXTRACTION THROUGH SPERMICIDES AND MICROBICIDES
US20040248942A1 (en) * 2003-02-20 2004-12-09 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
WO2004099182A1 (en) 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Zinc salt of (s)-omeprazole
US20060235053A1 (en) 2003-05-06 2006-10-19 Atlanta Pharma Ag Agents for the treatment of lower abdominal disorders
MXPA06000543A (es) * 2003-07-17 2006-03-30 Univ Columbia Composiciones antimicrobianas que contienen combinaciones sinergicas de compuestos de amonio cuaternario y aceites esenciales y/o constituyentes de estos.
AU2004260832A1 (en) 2003-07-23 2005-02-10 Nycomed Gmbh Alkaline salts of proton pump inhibitors
US20050244517A1 (en) * 2003-11-05 2005-11-03 Santarus, Inc. Combination of proton pump inhibitor and sleep aid
US20050238731A1 (en) * 2003-12-29 2005-10-27 Stephen Holt Composition and method for treating the effects of diseases and maladies of the upper digestive tract
EP1718303A4 (en) 2004-02-10 2010-09-01 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG
JP2008526771A (ja) 2004-12-30 2008-07-24 ジェンザイム コーポレーション 高リン酸血症のための亜鉛含有処置
WO2006073779A1 (en) 2004-12-30 2006-07-13 Transform Phamaceuticals, Inc. Novel omeprazole forms and related methods
CN100515491C (zh) * 2005-01-04 2009-07-22 健能隆医药技术（上海）有限公司 白介素-22的医药用途
US20060230553A1 (en) * 2005-04-14 2006-10-19 Helmut Thullen Process for tinting, dyeing or doping of moulded components made of transparent (co)polyamides in aqueous dye bath
US20060251722A1 (en) * 2005-05-03 2006-11-09 Novavax, Inc. Multi-component vitamin and mineral supplement for the optimal absorption of components
US8512761B2 (en) * 2006-01-27 2013-08-20 Yale University Fast acting inhibitor of gastric acid secretion
US11510894B2 (en) 2006-01-27 2022-11-29 John P. Geibel Fast acting inhibitor of gastric acid secretion

Also Published As

Publication number Publication date
JP6366548B2 (ja) 2018-08-01
PT1976532E (pt) 2016-02-11
ES2562059T3 (es) 2016-03-02
CN101374526A (zh) 2009-02-25
JP5469865B2 (ja) 2014-04-16
HK1191861A1 (zh) 2014-08-08
CN103463096A (zh) 2013-12-25
ES2609976T3 (es) 2017-04-25
EP1976532B1 (en) 2015-11-11
EP2705845A1 (en) 2014-03-12
WO2007089511A3 (en) 2008-04-10
HRP20151437T1 (hr) 2016-02-12
EP1976532A4 (en) 2010-12-15
RS54543B1 (en) 2016-06-30
US11510894B2 (en) 2022-11-29
EP1976532A2 (en) 2008-10-08
JP2009524669A (ja) 2009-07-02
CA2635272A1 (en) 2007-08-09
EP2705845B1 (en) 2016-10-05
JP2015232016A (ja) 2015-12-24
SI1976532T1 (sl) 2016-04-29
WO2007089511A2 (en) 2007-08-09
HUE029222T2 (en) 2017-02-28
US20090035393A1 (en) 2009-02-05
PL1976532T3 (pl) 2016-05-31
CN101374526B (zh) 2013-08-07
JP2013241457A (ja) 2013-12-05
CN103463096B (zh) 2016-03-16
CA2635272C (en) 2016-11-29

Similar Documents

Publication Publication Date Title
DK1976532T3 (da) Hurtigvirkende inhibitor af mavesyresekretion
US10603339B2 (en) Fast acting inhibitor of gastric acid secretion
JP2007522182A (ja) プロトンポンプ阻害剤の新規使用
Blum Lansoprazole and omeprazole in the treatment of acid peptic disorders
RU2603462C2 (ru) Лечение фармакологически индуцированной гипохлоргидрии
Adachi et al. Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori-negative subjects: effects of different regimens
Mohamed et al. The rationale of acid suppression in the treatment of acid‐related disease.
AU2006274905B2 (en) Combination of Itriglumide and proton pump inhibitors in the treatment of gastrointestinal and related disorders
KR20010024050A (ko) 항균제
Onodera et al. Unique Profile of Lafutidine, A Novel Histamine H2-Receptor Antagonist-Mucosal Protection Throughout Gastrointestinal Tract Mediated by Capsaicin-Sensitive Afferent Neurons
ES2425398T3 (es) Antagonistas de receptor de colecistocinina-1 (CCK1) en el tratamiento de trastornos gastrointestinales y relacionados
JP5410816B2 (ja) 小腸粘膜障害の予防・治療薬剤としての医薬組成物
RU2347566C1 (ru) СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЖЕЛУДКА И ДВЕНАДЦАТИПЕРСТНОЙ КИШКИ, ВЫЗВАННЫХ Helicobacter pylori, МОДИФИЦИРОВАННЫЙ ЗАМЕДЛЕНИЕМ КЛИРЕНСА СЛИЗИСТОЙ ОБОЛОЧКИ ОТ ХИМИОТЕРАПЕВТИЧЕСКИХ СРЕДСТВ ХОЛИНОЛИТИКОМ